{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:18:07Z","timestamp":1786648687954,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005297","name":"Medical University of Bialystok","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clinthera.2026.04.019","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:16:17Z","timestamp":1779794177000},"page":"781-789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Noninvasive Biomarkers for Graves\u2019 Orbitopathy: Clinical Relevance of Circulating PAI-1, TGF-\u03b2 and IGF-1R"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9910-8537","authenticated-orcid":false,"given":"Diana","family":"Leszczy\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Pomichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Szelachowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Buczy\u0144ska-Backiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Adamska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pop\u0142awska-Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ko\u015bciuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Bonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"Bugajewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam Jacek","family":"Kr\u0119towski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Siewko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.04.019_bib0001","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of graves\u2019 orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0003","doi-asserted-by":"crossref","first-page":"313","DOI":"10.30574\/wjarr.2024.21.2.0437","article-title":"Graves\u2019 orbitopathy: what\u2019s new? Case report with diagnostic and therapeutic update","volume":"21","author":"Jadi","year":"2024","journal-title":"World J Adv Res Rev"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0004","article-title":"Graves\u2019 ophthalmopathy: VISA versus EUGOGO classification, assessment, and management","volume":"2015","author":"Barrio-Barrio","year":"2015","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0005","article-title":"Current concepts regarding Graves\u2019 orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0006","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0007","article-title":"Treatment of thyroid orbitopathy (Graves Orbitopathy) based on EUGOGO 2021 guidelines, with focus on Polish reality","volume":"100","author":"Durma","year":"2022","journal-title":"Lek Wojsk"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0008","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.14-14002","article-title":"Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy","volume":"55","author":"Wang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1292519","article-title":"Predictive markers for anti-inflammatory treatment response in thyroid eye disease","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0010","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/cells13171493","article-title":"A review of pathophysiology and therapeutic strategies targeting TGF-\u03b2 in graves\u2019 ophthalmopathy","volume":"13","author":"Ghiam","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0011","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-15-0524","article-title":"Cell density-dependent stimulation of PAI-1 and hyaluronan synthesis by TGF-\u03b2 in orbital fibroblasts","volume":"229","author":"Galgoczi","year":"2016","journal-title":"J Endocrinol"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/biom12111620","article-title":"Tears as a source of biomarkers in the diagnosis of graves\u2019 orbitopathy","volume":"12","author":"Bajkowska","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0013","doi-asserted-by":"crossref","DOI":"10.1097\/ICU.0b013e3283499446","article-title":"The pathophysiology of thyroid eye disease: implications for immunotherapy","volume":"22","author":"Douglas","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0014","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac252","article-title":"Future projections in thyroid eye disease","volume":"107","author":"Barbesino","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0015","article-title":"Management of patients with Graves\u2019 orbitopathy: Initial assessment, management outside specialised centres and referral pathways","volume":"15","author":"Perros","year":"2015","journal-title":"Clin Med J Royal Coll Phys London"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0016","first-page":"98","article-title":"Factors affecting the course of Graves\u2019orbitopathy and poor response to glucocorticoid treatment followed by orbital radiotherapy","volume":"9","author":"Jagie\u0142\u0142o-Korzeniowska","year":"2022","journal-title":"OphthaTherapy Therap Ophthalmol"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5114\/ceji.2018.80224","article-title":"Clinical utility of TSH receptor antibody levels in Graves\u2019 orbitopathy: a comparison of two TSH receptor antibody immunoassays","volume":"43","author":"Bluszcz","year":"2018","journal-title":"Cent Eur J Immunol"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0018","doi-asserted-by":"crossref","DOI":"10.2147\/JIR.S307046","article-title":"The 4g\/5g polymorphism of plasminogen activator inhibitor type 1 is a predictor of moderate-to-severe thyroid eye disease","volume":"14","author":"Katko","year":"2021","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0019","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/thy.2011.0248","article-title":"Graves\u2019 orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines","volume":"22","author":"Ujhelyi","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0020","article-title":"Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves\u2019 hyperthyroidism","volume":"146","author":"Wahrenberg","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19250","article-title":"Roles of four targets in the pathogenesis of graves\u2019 orbitopathy","volume":"9","author":"Ren","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2018.11.004","article-title":"Molecular biomarkers of Graves\u2019 ophthalmopathy","volume":"106","author":"Longo","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0023","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/cen.14178","article-title":"Low signal intensities of MRI T1 mapping predict refractory diplopia in Graves\u2019 ophthalmopathy","volume":"92","author":"Matsuzawa","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0024","doi-asserted-by":"crossref","DOI":"10.1159\/000242477","article-title":"Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes","volume":"30","author":"Seo","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0025","first-page":"1","article-title":"TGF-\u03b2 signaling in health, disease and therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0026","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0027","doi-asserted-by":"crossref","DOI":"10.1124\/pr.109.002469","article-title":"Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?","volume":"62","author":"Smith","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0028","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2011.10.002","article-title":"Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves\u2019 orbitopathy","volume":"26","author":"Smith","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0030","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-018-0943-8","article-title":"Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves\u2019 disease and Graves\u2019 orbitopathy","volume":"42","author":"Marin\u00f2","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0031","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1210\/clinem\/dgaa124","article-title":"Evidence for associations between Th1\/Th17 \u201chybrid\u201d phenotype and altered lipometabolism in very severe graves orbitopathy","volume":"105","author":"Fang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0032","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3390\/genes14061209","article-title":"Associations between lipid profiles and graves\u2019 orbitopathy can be HLA-dependent","volume":"14","author":"Stasiak","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0033","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.81.P467","article-title":"Vitamin D levels in patients with graves orbitopathy","author":"Boutzios","year":"2022","journal-title":"Endocrine Abstracts"},{"key":"10.1016\/j.clinthera.2026.04.019_bib0034","article-title":"Immunomodulatory function of vitamin D and its role in autoimmune thyroid disease","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:02:10Z","timestamp":1783692130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826001372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0149291826001372"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninvasive Biomarkers for Graves\u2019 Orbitopathy: Clinical Relevance of Circulating PAI-1, TGF-\u03b2 and IGF-1R","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}